Compare McDonald's Corp (MCD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Recursion Pharmaceuticals Inc — how do they compare? McDonald's Corp trades at $235.81 (market cap $163.38B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: McDonald's Corp is far larger — about 70.7× Recursion Pharmaceuticals Inc's market cap, and McDonald's Corp pays a 3.34% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MCD | RXRX | |
|---|---|---|
Market Cap | $163.38B | $2.31B |
Volume | 4,647,229 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $6.79 |
52-Week Low | $230.88 | $2.84 |
Typical Hold Time | 164 Days | 22 Days |
Enterprise Value | $217.15B | $1.83B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $236.9, up 1.91% for the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $26.89B and net income of $8.56B, supported by a 57.38% gross margin. Recent news highlights a new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $286.95 price target, but technical indicators and macroeconomic headwinds pose risks. Investment opportunity lies in McDonald's resilient franchise model and dividend yield, though inflation and execution of new initiatives are key watchpoints for shareholders.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
